Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

| Filed by the Registrant                    |     | ☒ |
| Filed by a Party other than the Registrant |     | ☐ |

Check the appropriate box:

| ☐ |     | Preliminary Proxy Statement                                                     |
| ☐ |     | Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
| ☒ |     | Definitive Proxy Statement                                                      |
| ☐ |     | Definitive Additional Materials                                                 |
| ☐ |     | Soliciting Material Pursuant to § 240.14a-12                                    |

Atara Biotherapeutics, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required.                                                                                     |
| ☐ | Fee paid previously with preliminary materials.                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

ATARA BIOTHERAPEUTICS, INC. 1280 Rancho Conejo Boulevard Thousand Oaks, CA 91320 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held on June 10, 2025 Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders (the “Annual Meeting”) of A tara B iotherapeutics , I nc . , a Delaware corporation. The meeting will be held virtually via live audio webcast on June 10, 2025 at 9:00 a.m. Pacific time for the following purposes: 1. To elect our three nominees for director named in the accompanying Proxy Statement to hold office until the 2028 Annual Meeting of Stockholders; 2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement accompanying this Notice; 3. To approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executive officers; 4. To ratify the selection by the Audit Committee of our Board of Directors of Deloitte & Tou